AKTX Celsus Therapeutics PLC

Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia

Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia
EN
06/10/2020

Underlying

AKTXCelsus Therapeutics PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celsus Therapeutics PLC

 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 P...

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 Access the Akari CEO Corner  TAMPA, Fla. and LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala. In this segment, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, provides a corporate update highlighting t...

January 9, 2026 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics to Present at the 2026 Biotech Showcase

Akari Therapeutics to Present at the 2026 Biotech Showcase In-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, strategic priorities and key milestones for 2026 TAMPA, Fla. and LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the  being he...

January 8, 2026 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the following letter to shareholders from its President and Chief Executive Officer, Abizer Gaslightwala.                                    Dear Fellow Shareholders, As 2025 concludes, I am pleased to reflect on a year of meaningful progress and significant achievements towards creating best-in-class ADCs to transfor...

December 30, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program...

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced the initiation of GMP manufacturing activities to support the development of AKTX-101, the Company’s lead ADC program. Akari has selected WuXi XDC, the world’s leading ...

December 23, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Akari Therapeutics Releases Virtual Investor “What This Means” Segment TAMPA, Fla. and LONDON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a . As part of the segment, Mr. Gaslightwala discussed the Company’s novel spliceosome modulating payload, PH1, and Akari’s ongoing efforts to demonstrate the potential of using this ADC payload against some of the toughest cancers t...

December 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch